Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022

More articles from Editorial

  • You have access
    Biochemical markers of bone turnover: Useful but underused
    Angelo A. Licata, MD
    Cleveland Clinic Journal of Medicine October 2008, 75 (10) 751-752;

    Markers tell us the risk of fracture and are useful in patient management. But will insurance pay for testing?

  • You have access
    Preventing renal disease progression: Can complete renin-angiotensin- aldosterone blockade work?
    Martin J. Schreiber, MD
    Cleveland Clinic Journal of Medicine October 2008, 75 (10) 699-704;

    In view of the risks of complete blockade of the renin-angiotensin- aldosterone pathway, more data from clinical trials are needed before the general medical community widely applies this strategy to prevent progressive chronic kidney disease.

  • You have access
    Given the ENHANCE trial results, ezetimibe is still unproven
    Allen J. Taylor, MD
    Cleveland Clinic Journal of Medicine July 2008, 75 (7) 497-506;

    We should beware of explaining away results that do not match our expectations.

  • You have access
    How safe are erythropoiesis-stimulating agents?
    Alan E. Lichtin, MD
    Cleveland Clinic Journal of Medicine May 2008, 75 (5) 359-360;

    The year 2007 was a rough one for these agents, and the story is far from over.

  • You have access
    Gadolinium and nephrogenic systemic fibrosis: The evidence of things not seen
    Jonathan Kay, MD
    Cleveland Clinic Journal of Medicine February 2008, 75 (2) 112-117;

    Much has been learned, but "nephrogenic" is misleading: this fibrosing disorder is not caused by the kidneys.

  • You have access
    Prostate cancer: Too much dogma, not enough data
    Derek Raghavan, MD, PhD, FRACP
    Cleveland Clinic Journal of Medicine January 2008, 75 (1) 33-34;

    In our management of prostate cancer, dogma often outweighs real data. Well-designed, randomized clinical trials are the answer.

  • You have access
    Acute aortic syndromes: Time to talk of many things
    Lars G. Svensson, MD, PhD
    Cleveland Clinic Journal of Medicine January 2008, 75 (1) 25-29;

    Lewis Carroll’s poem of 1872 is a useful starting point for identifying issues resulting from confusion over the various acute aortic syndromes.

  • You have access
    Exposing the complexity of HDL
    Stephen J. Nicholls, MBBS, PhD
    Cleveland Clinic Journal of Medicine October 2007, 74 (10) 709-712;

    HDL is a heterogeneous population of particles, and we should not be surprised if these particles differ in their effect on the arterial wall.

  • You have access
    Implications of the Spine Patient Outcomes Research Trial in the clinical management of lumbar disk herniation
    Gordon R. Bell, MD
    Cleveland Clinic Journal of Medicine August 2007, 74 (8) 572-576;

    What information does the Spine Patient Outcomes Research Trial offer for patients with lumbar radiculopathy and for their clinicians?

  • You have access
    Perhaps it is time for a change in policy on lung cancer screening
    David F. Yankelevitz, MD
    Cleveland Clinic Journal of Medicine June 2007, 74 (6) 438-440;

    It is time to think seriously about using computed tomography as a screening test for lung cancer. We should include members of society beyond the scientific community in making this decision.

Pages

  • Previous
  • Next
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 28

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire